Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice

Gastroenterology

Volumn 151, Issue 6, 2016, Pages 1218-1231

  Jandaghi, Pouria ^a,b   Najafabadi, Hamed S ^b   Bauer, Andrea S ^a   Papadakis, Andreas I ^b,c   Fassan, Matteo ^d   Hall, Anita ^c,e   Monast, Anie ^c   von Knebel Doeberitz, Magnus ^f   Neoptolemos, John P ^g   Costello, Eithne ^g   Greenhalf, William ^g   Scarpa, Aldo ^d,h   Sipos, Bence ⁱ   Auld, Daniel ^b   Lathrop, Mark ^b   Park, Morag ^b,c   Büchler, Markus W ^f   Strobel, Oliver ^f   Hackert, Thilo ^f   Giese, Nathalia A ^f   Zogopoulos, George ^c,e   Sangwan, Veena ^b,c   Huang, Sidong ^b,c   Riazalhosseini, Yasser ^b   Hoheisel, Jörg D ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^h UNIVERSITY OF VERONA   (Italy)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Drug Repositioning; Pancreas; TMA; Unfolded Protein Response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CASPASE 3; CASPASE 7; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; MESSENGER RNA; PIMOZIDE; PROTEIN PERK; TRANSCRIPTOME; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; DRD2 PROTEIN, HUMAN; DRD2 PROTEIN, MOUSE; PERK KINASE; PROTEIN KINASE R; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CELL MIGRATION; CELL PROLIFERATION; CHRONIC PANCREATITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRD2 GENE; ENDOPLASMIC RETICULUM STRESS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR GENE; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR VOLUME; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANIMAL; CASE CONTROL STUDY; CELL CYCLE CHECKPOINT; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; SECONDARY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE D2 RECEPTOR ANTAGONISTS; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HALOPERIDOL; HUMANS; MALE; MICE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PIMOZIDE; RECEPTORS, DOPAMINE D2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTOME; UNFOLDED PROTEIN RESPONSE; UP-REGULATION;

EID: 84997170986     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.08.040     Document Type: Article

References (39)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. 2 Costello, E., Greenhalf, W., Neoptolemos, J.P., New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9 (2012), 435–444.
3. 3 Trouilloud, I., Dubreuil, O., Boussaha, T., et al. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 35 (2011), 364–374.
4. 4 Kim, M.P., Gallick, G.E., Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14 (2008), 1284–1285.
5. 5 de Souza Rocha Simonini, P., Breiling, A., Gupta, N., et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70 (2010), 9175–9184.
6. 6 Kanehisa, M., Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28 (2000), 27–30.
7. 7 Gold, M.G., Gonen, T., Scott, J.D., Local cAMP signaling in disease at a glance. J Cell Sci 126 (2013), 4537–4543.
8. 8 Neves, S.R., Ram, P.T., Iyengar, R., G protein pathways. Science 296 (2002), 1636–1639.
9. 9 Menche, J., Sharma, A., Kitsak, M., et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science, 347, 2015, 1257601.
10. 10 Zimmerman, N.P., Roy, I., Hauser, A.D., et al. Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Mol Carcinog 54 (2015), 203–215.
11. 11 Bang, U.C., Benfield, T., Hyldstrup, L., et al. Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study. Gastroenterology 146 (2014), 989–994.
12. 12 Scholzen, T., Gerdes, J., The Ki-67 protein: from the known and the unknown. J Cell Physiol 182 (2000), 311–322.
13. 13 Mothi, M., Sampson, S., Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev, 11, 2013, CD001949.
14. 14 Bowery, B.J., Razzaque, Z., Emms, F., et al. Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626. Br J Pharmacol 119 (1996), 1491–1497.
15. 15 Tinsley, R.B., Bye, C.R., Parish, C.L., et al. Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 66 (2009), 472–484.
16. 16 Clarke, H.J., Chambers, J.E., Liniker, E., et al. Endoplasmic reticulum stress in malignancy. Cancer Cell 25 (2014), 563–573.
17. 17 Stutzmann, G.E., Mattson, M.P., Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease. Pharmacol Rev 63 (2011), 700–727.
18. 18 Tovey, S.C., Dedos, S.G., Rahman, T., et al. Regulation of inositol 1,4,5-trisphosphate receptors by cAMP independent of cAMP-dependent protein kinase. J Biol Chem 285 (2010), 12979–12989.
19. 19 Holz, G.G., Leech, C.A., Heller, R.S., et al. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 274 (1999), 14147–14156.
20. 20 Li, L., Miyamoto, M., Ebihara, Y., et al. DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma. World J Surg 30 (2006), 1672–1679 discussion 1680–1681.
21. 21 Davies, S.P., Reddy, H., Caivano, M., et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000), 95–105.
22. 22 Freyberg, Z., Ferrando, S.J., Javitch, J.A., Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167 (2010), 388–396.
23. 23 Arguello, P.A., Gogos, J.A., A signaling pathway AKTing up in schizophrenia. J Clin Invest 118 (2008), 2018–2021.
24. 24 Hamanaka, R.B., Bennett, B.S., Cullinan, S.B., et al. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol Biol Cell 16 (2005), 5493–5501.
25. 25 Brewer, J.W., Hendershot, L.M., Sherr, C.J., et al. Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc Natl Acad Sci U S A 96 (1999), 8505–8510.
26. 26 Maly, D.J., Papa, F.R., Druggable sensors of the unfolded protein response. Nat Chem Biol 10 (2014), 892–901.
27. 27 Lytton, J., Westlin, M., Hanley, M.R., Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem, 266, 1991 17067–1771.
28. 28 Granger, B., Albu, S., The haloperidol story. Ann Clin Psychiatry 17 (2005), 137–140.
29. 29 Li, J., Zhu, S., Kozono, D., et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 5 (2014), 882–893.
30. 30 Yang, Z.J., Chee, C.E., Huang, S., et al. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10 (2011), 1533–1541.
31. 31 Mollereau, B., Establishing links between endoplasmic reticulum-mediated hormesis and cancer. Mol Cell Biol 33 (2013), 2372–2374.
32. 32 Li, X., Zhang, K., Li, Z., Unfolded protein response in cancer: the physician's perspective. J Hematol Oncol, 4, 2011, 8.
33. 33 Liu, Y., Ye, Y., Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Res 21 (2011), 867–883.
34. 34 Sachlos, E., Risueno, R.M., Laronde, S., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149 (2012), 1284–1297.
35. 35 Dalton, S.O., Mellemkjaer, L., Thomassen, L., et al. Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969–1993. Schizophr Res 75 (2005), 315–324.
36. 36 Driver, J.A., Logroscino, G., Buring, J.E., et al. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16 (2007), 1260–1265.
37. 37 Neifeld, J.P., Tormey, D.C., Baker, M.A., et al. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients. Cancer Treat Rep 67 (1983), 155–157.
38. 38 Collisson, E.A., Sadanandam, A., Olson, P., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17 (2011), 500–503.
39. 39 Daemen, A., Peterson, D., Sahu, N., et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci U S A 112 (2015), E4410–E4417.